Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 30 of 40 results for mucus

  1. Transvaginal laser therapy for urogenital atrophy (IPG697)

    Evidence-based recommendations on transvaginal laser therapy for urogenital atrophy. This involves using a laser in the vagina to increase its strength and elasticity, to improve symptoms of urogenital atrophy.

  2. Endobronchial valve insertion to reduce lung volume in emphysema (IPG600)

    Evidence-based recommendations on endobronchial valve insertion to reduce lung volume in emphysema. This involves placing small one-way valves in some airways leading to damaged parts of the lungs.

  3. Fertility problems: assessment and treatment (CG156)

    This guideline covers diagnosing and treating fertility problems. It aims to reduce variation in practice and improve the way fertility problems are investigated and managed.

  4. Urinary incontinence and pelvic organ prolapse in women. Patient decision aid on surgery for uterine prolapse

    to the toilet in time, bleeding from the back passage (anus) or passing mucus. NICE thinks that constipation is more likely after sacro-...

  5. Laparoscopic ventral mesh rectopexy for internal rectal prolapse (IPG618)

    Evidence-based recommendations on laparoscopic ventral mesh rectopexy for internal rectal prolapse in adults. This involves using a piece of sterile material (mesh) to attach the rectum to the lower back bone using keyhole surgery.

  6. Otovent nasal balloon for otitis media with effusion (MIB59)

    NICE has developed a medtech innovation briefing (MIB) on the Otovent nasal balloon for otitis media with effusion

  7. Complete cytoreduction for pseudomyxoma peritonei (Sugarbaker technique) (IPG56)

    Evidence-based recommendations on complete cytoreduction for pseudomyxoma peritonei (Sugarbaker technique). This involves complete surgical tumour removal with intraoperative heated chemotherapy, and is followed by postoperative intraperitoneal chemotherapy.

  8. Combined endoscopic and laparoscopic removal of colonic polyps (IPG503)

    Evidence-based recommendations on combined endoscopic and laparoscopic removal of colonic polyps. This involves using an endoscope in the bowel plus keyhole surgery through the skin of the abdomen to remove colonic polyps.

  9. Transabdominal artificial bowel sphincter implantation for faecal incontinence (IPG276)

    Evidence-based recommendations on transabdominal artifical bowel sphincter implantation for faecal incontinence. This involves inserting an artificial sphincter through a cut in the abdomen.

  10. Endoscopic full thickness removal of non-lifting colonic polyps (IPG580)

    Evidence-based recommendations on endoscopic full thickness removal of non-lifting colonic polyps. This involves using a special device to remove the polyp and seal the bowel wall closed afterwards.

  11. Ambu aScope 4 Broncho for routine diagnostic and therapeutic bronchoscopy (MIB314)

    NICE has developed a medtech innovation briefing (MIB) on Ambu aScope 4 Broncho for routine diagnostic and therapeutic bronchoscopy .

  12. Urinary incontinence and pelvic organ prolapse in women. Patient decision aid on treating complications from mesh used for pelvic organ prolapse – Options for women referred to specialist centres

    bowels, not getting to the toilet in time, bleeding from the anus or passing mucus. : There may not be an obvious cause for some other...

  13. NaviCam for diagnosing gastrointestinal tract conditions (MIB104)

    NICE has developed a medtech innovation briefing (MIB) on NaviCam for diagnosing gastrointestinal tract conditions .

  14. Diverticular disease: diagnosis and management (NG147)

    This guideline covers the diagnosis and management of diverticular disease in people aged 18 years and over. It aims to improve diagnosis and care and help people get timely information and advice, including advice about symptoms and when to seek help.

  15. Risankizumab for previously treated moderately to severely active Crohn's disease (TA888)

    Evidence-based recommendations on risankizumab (Skyrizi) for previously treated moderately to severely active Crohn's disease in people 16 years and over.